Boston Family Office LLC Purchases Shares of 11,403 Kenvue Inc. (NYSE:KVUE)

Boston Family Office LLC acquired a new position in shares of Kenvue Inc. (NYSE:KVUE) in the 4th quarter, Holdings Channel reports. The fund acquired 11,403 shares of the company’s stock, valued at approximately $243,000.

Several other institutional investors also recently modified their holdings of KVUE. Handelsbanken Fonder AB lifted its stake in Kenvue by 2.9% during the fourth quarter. Handelsbanken Fonder AB now owns 742,184 shares of the company’s stock worth $15,846,000 after purchasing an additional 21,222 shares during the last quarter. Alberta Investment Management Corp boosted its stake in Kenvue by 23.2% in the fourth quarter. Alberta Investment Management Corp now owns 582,895 shares of the company’s stock worth $12,445,000 after buying an additional 109,700 shares in the last quarter. Longbow Finance SA grew its position in Kenvue by 5.0% during the fourth quarter. Longbow Finance SA now owns 280,568 shares of the company’s stock valued at $5,990,000 after acquiring an additional 13,287 shares during the last quarter. Steward Partners Investment Advisory LLC raised its stake in shares of Kenvue by 143.1% during the fourth quarter. Steward Partners Investment Advisory LLC now owns 47,938 shares of the company’s stock worth $1,023,000 after acquiring an additional 28,216 shares in the last quarter. Finally, CORDA Investment Management LLC. lifted its holdings in shares of Kenvue by 1.4% in the 4th quarter. CORDA Investment Management LLC. now owns 1,253,096 shares of the company’s stock worth $26,754,000 after acquiring an additional 17,466 shares during the last quarter. 97.64% of the stock is currently owned by institutional investors.

Kenvue Price Performance

Shares of NYSE KVUE opened at $23.85 on Wednesday. The company has a debt-to-equity ratio of 0.66, a current ratio of 1.00 and a quick ratio of 0.69. Kenvue Inc. has a 1 year low of $17.67 and a 1 year high of $24.46. The company’s 50-day moving average is $22.44 and its 200 day moving average is $22.46. The stock has a market capitalization of $45.57 billion, a P/E ratio of 44.99, a P/E/G ratio of 2.62 and a beta of 1.25.

Kenvue (NYSE:KVUE) last announced its earnings results on Thursday, February 6th. The company reported $0.26 earnings per share (EPS) for the quarter, hitting the consensus estimate of $0.26. Kenvue had a return on equity of 20.97% and a net margin of 6.66%. On average, sell-side analysts expect that Kenvue Inc. will post 1.14 earnings per share for the current year.

Kenvue Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Wednesday, February 26th. Stockholders of record on Wednesday, February 12th were given a $0.205 dividend. This represents a $0.82 dividend on an annualized basis and a dividend yield of 3.44%. The ex-dividend date was Wednesday, February 12th. Kenvue’s dividend payout ratio is presently 154.72%.

Wall Street Analyst Weigh In

Several research firms recently commented on KVUE. Evercore ISI initiated coverage on shares of Kenvue in a report on Monday, March 24th. They set an “in-line” rating and a $25.00 target price on the stock. Canaccord Genuity Group lifted their price objective on Kenvue from $24.00 to $29.00 and gave the stock a “buy” rating in a report on Wednesday, March 5th. Royal Bank of Canada restated a “sector perform” rating and set a $24.00 target price on shares of Kenvue in a report on Monday, February 3rd. Deutsche Bank Aktiengesellschaft downgraded Kenvue from a “buy” rating to a “hold” rating and lowered their price objective for the company from $25.00 to $24.00 in a research report on Thursday, December 12th. Finally, Citigroup cut their target price on shares of Kenvue from $25.00 to $21.00 and set a “neutral” rating on the stock in a report on Wednesday, January 15th. One research analyst has rated the stock with a sell rating, eight have assigned a hold rating and five have given a buy rating to the stock. Based on data from MarketBeat, Kenvue presently has an average rating of “Hold” and an average target price of $24.00.

About Kenvue

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.